TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03475004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.

Intervention type: DRUG
Group type: OTHER
Intervention: Binimetinib
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
Study: NCT03645122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired corticospinal-motoneuronal stimulation (PCMS)
Description: Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired corticospinal-motoneuronal stimulation (PCMS)
Description: Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
Study: NCT04324827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Technique
Description: FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Technique
Description: FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretch exercise
Description: Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
Study: NCT01779765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PHGG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT02961894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revolution™ Peripheral Atherectomy System
Description: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
Study: NCT00541658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
Study: NCT00505284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (2 mg)
Description: Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Study: NCT02867436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Study: NCT03043417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHC's given the intervention
Description: CHC's NOT given the intervention
Study: NCT04353141

Intervention type: DIAGNOSTIC_TEST
Intervention: standardized Lung Ultrasound (LUS) examination
Description: 14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
Study: NCT00505284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (4 mg)
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (6 mg)
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Study: NCT04353141

Intervention type: DIAGNOSTIC_TEST
Intervention: standardized Lung Ultrasound (LUS) examination
Description: 14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally

Intervention type: DIAGNOSTIC_TEST
Intervention: standardized Lung Ultrasound (LUS) examination
Description: 14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
Study: NCT04411641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Tolebrutinib
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study: NCT03175679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
Study: NCT03774446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seliciclib
Description: Drug: Seliciclib
Study: NCT00505284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (8 mg)
Description: Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
Study: NCT00882154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg Capsule (Sandoz, Austria)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Study: NCT02320084

Intervention type: DRUG
Intervention: Nitisinone
Description: Nitisinone according to prescription
Study: NCT03548285

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
Study: NCT02419495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02872883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant management
Study: NCT02419495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT02872883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Vaginal examinations (only when necessary)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Vaginal examinations (only when necessary)
Study: NCT02419495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study: NCT02872883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active management
Study: NCT03205709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crossword Puzzles
Description: These are intended to mimic crossword puzzles in newspapers.
Study: NCT04310462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New e-prescribing interface
Description: The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
Study: NCT02872883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine vaginal examinations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine vaginal examinations
Study: NCT03598842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation Meal
Description: Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation Meal
Description: Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Study participants will be given a daily multivitamin to take for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Study participants will be given a daily multivitamin to take for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-parasitic medications
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-parasitic medications
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
Study: NCT01854723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to NPH insulin
Description: Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of insulin glargine
Description: Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
Study: NCT03143166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Tablet, film coated
Study: NCT03969004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion over 30 minutes
Study: NCT03467750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.
Study: NCT03008278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Give PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV